TNFRSF4 and cancer: Agonistic monoclonal antibody/antibodies (mAb) targeting co-stimulatory receptors have been under intensive clinical development for cancer therapy, in particular, tumor necrosis factor receptors (TNFR) superfamily members, such as CD40, 4-1BB, and OX40 [9].